WallStSmart

Merck & Company Inc (MRK)vsPrecision Optics Corporation, Inc. Common stock (POCI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 227167% more annual revenue ($65.77B vs $28.94M). MRK leads profitability with a 13.6% profit margin vs -17.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

POCI

Avoid

31

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.0Quality: 6.0
Piotroski: 3/9Altman Z: -2.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued
POCISignificantly Overvalued (-19.1%)

Margin of Safety

-19.1%

Fair Value

$4.20

Current Price

$5.53

$1.33 premium

UndervaluedFair: $4.20Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

POCI2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
108.0%10/10

Revenue surging 108.0% year-over-year

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

POCI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$62.17M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-29.6%2/10

ROE of -29.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : POCI

The strongest argument for POCI centers on Revenue Growth, Debt/Equity. Revenue growth of 108.0% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : POCI

The primary concerns for POCI are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

MRK profiles as a value stock while POCI is a hypergrowth play — different risk/reward profiles.

POCI carries more volatility with a beta of 0.23 — expect wider price swings.

POCI is growing revenue faster at 108.0% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Precision Optics Corporation, Inc. Common stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and lighting systems and related components primarily in the United States and the European Economic Area. The company is headquartered in Gardner, Massachusetts.

Want to dig deeper into these stocks?